United States
Germany
Japan
United Kingdom
China
Carrier-free (BSA/glycerol-free) GFAP mouse monoclonal antibody, clone OTI3F3
| Applications | ELISA |
| Reactivities | Human |
ELISA Kits
Carrier-free (BSA/glycerol-free) GFAP mouse monoclonal antibody, clone OTI2G10
| Applications | ELISA |
| Reactivities | Human |
Carrier-free (BSA/glycerol-free) ST2 mouse monoclonal antibody, clone OTI11A2
| Applications | ELISA |
| Reactivities | Human |
Carrier-free (BSA/glycerol-free) ST2 mouse monoclonal antibody, clone OTI3C10
| Applications | ELISA |
| Reactivities | Human |
Carrier-free (BSA/glycerol-free) ST2 mouse monoclonal antibody, clone OTI11E3
| Applications | ELISA |
| Reactivities | Human |
Carrier-free (BSA/glycerol-free) ST2 mouse monoclonal antibody, clone OTI10A2
| Applications | ELISA |
| Reactivities | Human |
Carrier-free (BSA/glycerol-free) ST2 mouse monoclonal antibody, clone OTI6G4
| Applications | ELISA |
| Reactivities | Human |
Carrier-free (BSA/glycerol-free) ST2 mouse monoclonal antibody, clone OTI8H4
| Applications | ELISA |
| Reactivities | Human |
Carrier-free (BSA/glycerol-free) ST2 mouse monoclonal antibody, clone OTI7E9
| Applications | ELISA |
| Reactivities | Human |
Carrier-free (BSA/glycerol-free) ST2 mouse monoclonal antibody, clone OTI4F4
| Applications | ELISA |
| Reactivities | Human |
Carrier-free (BSA/glycerol-free) ST2 mouse monoclonal antibody, clone OTI6C1
| Applications | ELISA |
| Reactivities | Human |
Carrier-free (BSA/glycerol-free) ST2 mouse monoclonal antibody, clone OTI9H9
| Applications | ELISA |
| Reactivities | Human |
Carrier-free (BSA/glycerol-free) ST2 mouse monoclonal antibody, clone OTI2F1
| Applications | ELISA |
| Reactivities | Human |
Carrier-free (BSA/glycerol-free) ST2 mouse monoclonal antibody, clone OTI1H5
| Applications | ELISA |
| Reactivities | Human |
Carrier-free (BSA/glycerol-free) ST2 mouse monoclonal antibody, clone OTI7E5
| Applications | ELISA |
| Reactivities | Human |
活动过滤器
优化搜索结果
Category
Target Symbol
- PGP9.5 (40)
- NGAL (36)
- IL6 (34)
- ST2 (34)
- GFAP (32)
- S100A8/A9 (29)
- D-DIMER (27)
- IL17 (27)
- MYELOPEROXIDASE (26)
- S PROTEIN (24)
- N PROTEIN (23)
- SERUM AMYLOID A (22)
- MYBPC3 (21)
- FABP3 (20)
- REG1 ALPHA (20)
- NEUROFILAMENT (14)
- IGG4 (12)
- S100 BETA (6)
- B7-1 (4)
- PD-L1 (4)
- PD1 (4)
- B RAF (3)
- PON1 (3)
- PSMA (3)
- SARS-COV-2 N PROTEIN (3)
- SARS-COV-2 SPIKE PROTEIN (3)
- BETA 2 MICROGLOBULIN (2)
- MSMB (2)
- NEFL (2)
- S100A1 (2)
- SERPINB3 (2)
Reactivities
Applications
Antibody Hosts
Knockout (KO) Validation
Conjugates
Isotypes
Clonalities
Assay Types
Brands
Families
Pathways
- Cytokine-cytokine receptor interaction (61)
- Hypertrophic cardiomyopathy (HCM) (55)
- Parkinson's disease (40)
- Graft-versus-host disease (38)
- Toll-like receptor signaling pathway (38)
- Pathways in cancer (37)
- Cytosolic DNA-sensing pathway (34)
- Hematopoietic cell lineage (34)
- Jak-STAT signaling pathway (34)
- NOD-like receptor signaling pathway (34)
- Prion diseases (34)
- Dilated cardiomyopathy (21)
- PPAR signaling pathway (20)
- Amyotrophic lateral sclerosis (ALS) (16)
- Cell adhesion molecules (CAMs) (12)
- Allograft rejection (4)
- Autoimmune thyroid disease (4)
- Systemic lupus erythematosus (4)
- T cell receptor signaling pathway (4)
- Type I diabetes mellitus (4)
- Viral myocarditis (4)
- Acute myeloid leukemia (3)
- Bladder cancer (3)
- Chemokine signaling pathway (3)
- Chronic myeloid leukemia (3)
- Colorectal cancer (3)
- Endometrial cancer (3)
- ErbB signaling pathway (3)
- Focal adhesion (3)
- Glioma (3)
- Insulin signaling pathway (3)
- Long-term depression (3)
- Long-term potentiation (3)
- MAPK signaling pathway (3)
- Melanoma (3)
- Metabolic pathways (3)
- Natural killer cell mediated cytotoxicity (3)
- Neurotrophin signaling pathway (3)
- Non-small cell lung cancer (3)
- Pancreatic cancer (3)
- Progesterone-mediated oocyte maturation (3)
- Prostate cancer (3)
- Regulation of actin cytoskeleton (3)
- Renal cell carcinoma (3)
- Thyroid cancer (3)
- Vascular smooth muscle contraction (3)
- mTOR signaling pathway (3)
- Antigen processing and presentation (2)
